Marco Maruzzo

Oncologo GU, ricercatore, libero pensatore | @iov_irccs | @UniPadova | @unipr | “Nella vita bisognerebbe essere sempre un po' improbabili”

[MV Chandrakanth @ChandrakanthMv]

• Surgery alone → ~50% relapse
• MVAC → survival breakthrough
• GC → better tolerability
• ddMVAC → superior 5-yr OS (VESPER)
• NIAGARA → chemo + IO improves OS
• EV + Pembro → platinum-free era?
#BladderCancer #GUOncology #ASCOGU #Immunotherapy #MVOnco

[Andrea Apolo, M.D. @apolo_andrea]

Beautiful discussion by @DrTylerStewart on the evolving treatment of MIBC that includes EVP and the use of DV in advanced #bladdercancer #GU26 @ASCO @tompowles1 @MattGalsky

[Andrea Apolo, M.D. @apolo_andrea]

The standard of care for MIBC will now include perioperative EVP for both cisplatin eligible and ineligible #BladderCancer pts. The EV304 study presented today @MattGalsky shows an improvement in EFS (HR 0.53) and OS (HR 0.65) for EVP over GC. @ASCO #GU26

[Jordan Ciuro, MD @jordanciuro]

Updates of STOPCAP? #GU25

STOPCAP shares 7 trials identifying who benefits from ARPi in mHSPC…
✅Benefit of intensification treatment of #mHSPC with ARPi in most patients in OS and PFS

Keep in mind…
📌Young patients have clear benefit from all ARPIs
📌More data needed in patients age >75
📌Limited patients received RT to prostate primary

🔎Highlights need for biomarkers to help decision making in mHSPC treatment. Watch out for future trials like #TripleSwitch to help personalize therapy

@ASCO @OncoAlert @GUOncologyNow @urotoday

[Yüksel Ürün @DrYukselUrun]

TALAPRO-2 Final OS Data: TALA+ENZA in 1L mCRPC @neerajaiims 👏👏👏
🧬TALA+ENZA significantly improves OS vs ENZA alone in all-comer mCRPC, rPFS benefit sustain.
No new safety signals.
@asco @oncoalert #GU25 #cancer #oncology @MikeSerzanMD @drenriquegrande @crisbergerot @reginabarcar @DRBakaloudiMD @abvilima @ReneeSaliby @yekeduz_emre @DrChoueiri @montypal @PGrivasMDPhD @CParkMD @OncLive @amerseburger

[Toni Choueiri, MD @DrChoueiri]

My dear friend @neerajaiims presenting #TALAPRO2 final OS analysis: TALA + ENZA significantly improved OS vs PBO + ENZA in 1L mCRPC (HR 0.796). rPFS benefit sustained (HR 0.667). Safety consistent with prior reports. Phenomenal! @DrAndreFay #KarimFizazi @ASCO #GU25 @OncoAlert

[Patrizia Giannatempo @giannatempopatr]

Wonderful day at the #SIURO2024 congress in Bologna! A great society that brings together Italian oncologists @therealmarcodoc,@DrIacovelli @DanieleRaggi83 urologists @paolo_gontero,@Pederfizzo and radiotherapists, followed by an unforgettable evening with friends @AssPalinuro

[Tom Powles @tompowles1]

Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024 @NEJM

[NEJM @NEJM]

Neoadjuvant chemotherapy plus durvalumab, followed by adjuvant durvalumab after cystectomy, led to event-free survival superior to that with neoadjuvant chemotherapy followed by cystectomy alone.

Full NIAGARA trial results: https://t.co/n8af0OisfY #ESMO24

[Tom Powles @tompowles1]

Tivozanib +/- nivolumab in IO pretreated M1 renal cancer showed retreatment with IO makes absolutely no difference. This is on top of CONTACT3 which showed the same thing.We need to stop retreating with IO.These data apply in the post adjuvant setting too without data #ESMO2024

[Roberto Iacovelli @DrIacovelli]

@ciccarese_c rocked the stage presenting preliminary data of TACITO trial investigating #FMT on #mRCC. Primary endpoint 1-y PFS met and no safety issues. Thanks to @gianluca1aniro leading the gastroenterology team & all coinvesigators for this significant achievement.
@OncoAlert

[Tom Powles @tompowles1]

Nectin-4 is the target for Enfortumab Vedotin and is widely expressed in UC (median 275/300) . EV302 is 1st randomised trial to explore its relationship with response. IHC results show no clear relationship between Nectin-4 and outcome (RR,PFS,OS) or PD-L1 #ESMO2024

[Tom Powles @tompowles1]

The 1st disitimab Vedotin (HER-2 MMAE ADC) & pembro showing 1st line response rates of 75% in HER 1-3+ UC. Toxicity profile looks distinct from EV (fatigue>skin). There is a global randomised phase 3 of DV & pembro vs standard chemotherapy. #ESMO24
@DrRosenbergMSK @MattGalsky

[Enrique Grande @drenriquegrande]

🚨 Exciting Update! 🚨 Our new EVITA (EV Ineligible criTeriA) criteria for identifying patients ineligible for the EV/Pembro combo in #metastaticurothelialcarcinoma has just been published in @EUplatinum!!!! This breakthrough could significantly reshape daily clinical practice! 🩺📈

👉To identify patients who may not be optimal candidates for EV/P if they meet at least two of the following criteria:
📍Hemoglobin A1c 8% (if this parameter is not available itcould be replaced by baseline glucose >150 mg/dl in 2consecutive blood samples 1 wk apart).
📍Grade 2 sensory or motor neuropathy.
📍Any corneal or retinal abnormality.
📍Creatinine clearance or glomerular filtration rate 45
ml/min.
📍ECOG performance status score 2.

A huge thank you to my co-authors and friends @AlisonBirtle and @UroDocAsh for their invaluable contributions in developing these criteria. 🙏

We acknowledge that the EVITA criteria may be a matter of debate and welcome comments and suggestions for improvement from readers. These criteria are based on the expected side effects and exclusion criteria in EV-based clinical trials.

Stay tuned for more data on the EVITA+ population, which will further explore opportunities for new drug development and better characterization of this group. This is an exciting step forward in personalized patient care! #Urology #CancerResearch #EVITACriteria #ClinicalPractice @OncoAlert @urotoday @GuardConsortium @myESMO @Uroweb @EAU_Uroonco @UroTarget @apolo_andrea @ERPlimackMD @giannatempopatr @ravikanesvaran @tompowles1 @PGrivasMDPhD @montypal @amerseburger @cdanicas @sonpavde @DrYukselUrun

Enjoy the reading!!!📑
https://t.co/AN1amYHxAO

[AIOM @AIOMtweet]

Le interviste del Congresso Nazionale #AIOMGiovani 2024 sono disponibili su AIOM Tv: https://t.co/pp83qlFt1w

@rossana_berardi @FilippoPietran4 @saverio_cinieri @LGerratana @therealmarcodoc @AlbertoPuccini @lorenzobellu @RobertoBoreaMD @angela_toss
#AIOMTv #giovanioncologi

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place #AUA24 #EAU24 #IBCG24 #ASCO24

Designed by @AmandaMyersMD #OncSurgery @MDAndersonNews

@PGrivasMDPhD @shilpaonc @UrogerliMD @SimaPorten @pjhensley11 @SWilliams_MD

[Toni Choueiri, MD @DrChoueiri]

Relevant presentation by Eva Katharina Masel on integrating #palliative care into the management of GU cancers! #ASCO24

@MedUni_Wien @ASCO @OncoAlert

[Yüksel Ürün @DrYukselUrun]

Enfortumab Vedotin consistently improves PFS and OS compared to chemotherapy, regardless of dose modifications,
⭕️ Dose modifications help manage EV-related side effects without compromising the treatment’s effectiveness.
⭕️Start with 1.25 mg/kg, reduce if needed!
@asco #asco24 @oncoalert @Uromigos @OncLive @CParkMD

[Tom Powles @tompowles1]

40% response rate for chemo +pembro in advanced penile cancer #ASCO24 HPV16-positive (cORR 55.6%) and TMB-high (cORR 75%) potentially enrich. Great investigator initiated study from LACOG and Fernando Maluf


[Toni Choueiri, MD @DrChoueiri]

Masterful presentation by #FernandoMaluf presenting results of the #HERCULES LACOG 2018 trial #ASCO24

⚪️ First trial to demonstrate efficacy of ICI in advanced penile cancer w/ manageable safety profile (cORR 42.4% by CR)
⚪️ Pembro + chemo as new Tx option for pts w/ advanced #PSCC

Congratulations to all investigators! @DrAndreFay

@ASCO @OncoAlert